CELL INTELLIGENCE · 肿瘤细胞治疗研究

人源 CAR-T22.19 治疗难治性儿童 B-ALL：指定患者队列的启示

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

CAR-T22.19 疗法在高危儿科人群中显示出良好的安全性特征和有前景的临床活性，其双靶向设计使 CD19 阴性白血病获得疾病控制。

现货型双 CAR-iNKT 细胞免疫治疗根除髓内及软脑膜高危 KMT2A 重排白血病

Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.

活细胞 Pick-Seq（LiP-Seq）：探究 CAR-T19 治疗后的超罕见套细胞淋巴瘤持续细胞

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

NKTR-255 联合 CD19-22 CAR-T 细胞疗法治疗难治性 B 细胞急性淋巴细胞白血病的 1 期临床试验

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.

靶向 CD19/20 的双特异性 CAR-T 细胞治疗复发/难治性 B 细胞非霍奇金淋巴瘤患者：一项 I/II 期试验

Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.

共转导 CAR-T 细胞靶向 CD19/CD22 预防 B 细胞 ALL 的 CAR-T 治疗后抗原阴性复发

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.

CD19/CD22 双特异性 CAR-T 细胞治疗 MRD 阳性成人 B 细胞急性淋巴细胞白血病：一项 I 期临床研究

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.

利用新型高灵敏度 aCD22 CAR 双靶向 CD19 与 CD22 治疗 B-ALL

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

CD34+CD19-CD22+ B 细胞祖细胞可能构成 CD19 靶向治疗患者表型逃逸的基础

CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.

CAR 与嵌合共刺激受体联用增强 T 细胞对低抗原密度的敏感性并促进持久性

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.